Skip to content

S. 2292 · 119th Congress (2025–2027)

Over-the-Counter Monograph Drug User Fee Amendments

This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA); revises procedures used by the Food and Drug Administration (FDA) to evaluate topical, nonprescription drugs (e.g., sunscreens); and requires the FDA to clarify the process through which a prescription drug may be switched to nonprescription status.

Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the FDA, rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective. The bill reauthorizes the collection of OMUFA fees from OTC drug facilities through FY2030 and revises methods for calculating such fees.

Separately, the bill requires the FDA to allow for the use of real-world evidence to demonstrate the safety and effectiveness of active ingredients in topical, nonprescription drugs. The FDA must consider nonclinical tests and other alternatives to animal testing in evaluating such drugs.

The FDA must also issue guidance to clarify the application process for nonprescription drugs, including applications to switch a prescription drug to nonprescription status. The FDA must plan to engage stakeholders in identifying drugs that are promising candidates for a switch. Moreover, applicants seeking a switch may request to meet with the FDA to develop a plan for the requisite application.

Finally, the Government Accountability Office must report on (1) the OTC monograph drug supply chain, and (2) the FDA’s handling of applications to switch a prescription drug to nonprescription status.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.

Reported

This bill’s path

This is S. 2292’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Jim Banks (R-IN)
Cosponsors
3 cosponsors

1 original · 2 later

  1. Sen. Tim Kaine (D-VA)· Original · Jul 15, 2025
  2. Sen. Jon Husted (R-OH)· Later · Jul 29, 2025
  3. Sen. Andy Kim (D-NJ)· Later · Jul 29, 2025
Policy area
Health
Subjects
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Supply chain
  • User charges and fees

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Jul 15, 2025 – Sep 8, 2025
    1. Referred to committee

      Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

      Sources
    2. Ordered reported

      Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

      Sources
    3. Reported by committee

      Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

      Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 15, 2025 · Markup Jul 30, 2025 · Reported Sep 8, 2025
    1. Jul 30, 2025 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (2)
  1. Over-the-Counter Monograph Drug User Fee Amendments

    Short title, Display title · Reported to Senate, Introduced in Senate

  2. A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.

    Official title · Introduced in Senate